UK Launches World-First Gonorrhoea Vaccine Amid Record Infection Surge

Published: 04 August ‘2025 | The English Chronicle Desk

In a groundbreaking move to combat the rapid rise of sexually transmitted infections, the UK today becomes the first country in the world to launch a nationwide vaccination programme against gonorrhoea. The rollout, announced earlier this year by NHS England, comes at a critical time, with confirmed diagnoses of the disease reaching an alarming 85,000 cases in 2023 — the highest figure since records began in 1918, and nearly three times the number recorded just a decade ago in 2012.

The Department of Health and Social Care (DHSC) has confirmed that sexual health clinics across England are now equipped to offer the vaccine free of charge to individuals considered most at risk. This includes gay and bisexual men who have a recent history of multiple sexual partners or a bacterial STI within the last 12 months.

Public Health and Prevention Minister Ashley Dalton described the move as a “major breakthrough” in addressing both the surging infection rates and the escalating danger posed by antibiotic-resistant strains of gonorrhoea. “This government’s world-first vaccination programme will help turn the tide on infections, as well as tackling head-on the growing threat of antibiotic resistance,” she said. “I strongly encourage anyone who is eligible to come forward for vaccination, to protect not only yourselves but also your sexual partners.”

While the vaccine is not a complete safeguard — offering between 32.7% to 42% effectiveness against gonorrhoea — public health experts believe it represents a vital tool in managing and reducing future outbreaks. The limited efficacy means that preventive measures, routine testing, and responsible sexual practices remain essential.

The vaccine being used is based on MenB, originally designed to protect against meningococcal B bacteria. However, data led by researchers at Imperial College London suggests that it can significantly reduce the risk of gonorrhoea infection and its complications. Their analysis estimates that the new vaccination programme could prevent up to 100,000 cases and save the NHS more than £7.9 million over the next decade in testing, treatment, and long-term healthcare costs.

Experts warn that gonorrhoea has increasingly shown resistance to the antibiotics traditionally used to treat it, making vaccination a much-needed preventive approach. The bacterial infection, which often presents with painful urination and discharge, can also be asymptomatic — leading to its unintentional spread and long-term complications such as infertility if left untreated.

Today’s rollout marks a new chapter in the fight against one of the world’s oldest and most persistent infections. While it is not a complete solution, the gonorrhoea vaccine adds a crucial line of defence, and public health authorities are hopeful it will make a meaningful impact in the years ahead.